Email us connect@hepdconnect.org
News Archive
8/5/20 Hepcludex approved by European Commission
6/2/20 MYR Pharmaceuticals receives positive opinion from EMA for Hepcludex for the treatment of chronic hepatitis delta
4/2/20 Coronavirus pandemic issues delay key Eiger's D-LIVR study
2/18/20 New Insights into Hepatitis B and Hepatitis Delta Virus Entry
1/2/19 Hepatitis Delta Has Higher Health Care, Cost Burden Than Hepatitis B
12/26/19 REP2139 demonstrates functional cure in both HBV, HDV
11/12/19 Eiger Announces Phase 2 LIFT Study During AASLD 2019
11/1/19 MYR Pharmaceuticals to Present on Myrcludex B During AASLD 2019
11/1/19 FDA Guidance to Help with Hepatitis Delta Drug Development
8/20/19 Pegylated Interferon Lambda Receives FDA Breakthrough Therapy Designation
7/29/19 Russia Plans Production of Myrcludex B
4/13/19 MYR Announces Phase 2 Myrcludex B Trial Data at The International Liver Congress 2019
4/11/19 Eiger Announces Phase 2 LIMT Hepatitis Delta Study Progress at The International Liver Congress 2019
3/5/19 MYR Pharma Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA
12/18/18 Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib
12/17/18 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib
9/28/18 Global Hepatitis Delta rates highest among HBV coinfected with risky behaviors
6/4/18 Digestive Disease Week: Hepatitis Delta: The 'Forgotten Virus' is Still Here
10/23/18 MYR Pharma Announces FDA Breakthrough Therapy Designation for Myrcludex B
9/5/17 Pegylated Interferon Lambda Receives FDA Orphan Drug Designation
7/27/17 Pegylated Interferon Lambda Receives FDA Fast Track Designation
5/25/17 MYR Pharma Announces Myrcludex B PRIME Designation by By The EMA
4/20/15 Lonafarnib Receives FDA Fast Track Designation
12/22/14 Lonafarnib Recieves Orphan Drug Designation by FDA and EMA